Pharmacia
This article was originally published in The Tan Sheet
Executive Summary
U.S. Rogaine sales fell 22% to $23 mil., worldwide revenue dropped 17% to $30 mil. in Q2, firm says July 25. Revenues for Nicorette, which Pharmacia sells in certain foreign markets and licenses to GlaxoSmithKline in U.S., declined 8% to $22 mil. in U.S., but jumped 16% to $63 mil. globally. Domestic consumer health segment saw sales fall 14% to $77 mil., while total consumer health revenue was $169 mil., up a slight 1%. Pharmacia posted net sales of $5.42 bil. for quarter, up 5%, and net income rose 20% to $844 mil. before costs from March 2000 merger with Monsanto. Including merger and restructuring costs, net income was up 54% to $737 mil. Merger resulted in cost savings of $216 mil. in Q2
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning